Healthcare company eTrueNorth on Tuesday announced a partnership with the US Department of Health and Human Services (HHS), the University of Wisconsin, Philips to validate BioIntelliSense Inc's US FDA-cleared BioSticker device for the early detection of COVID-19.

Under the US Army Medical Research Development Command (USAMRDC) funded award through the Medical Technology Enterprise Consortium (MTEC), the clinical trial is evaluating the use of wearable diagnostics for early identification and containment of COVID-19.

As part of the USARMRDC funded trial, the company will recruit 2,500 volunteers from 22 testing sites located at University of Wisconsin facilities. Participants in the study will be shipped a wearable medical device (BioIntelliSense's BioSticker with its BioHub wireless gateway).

Based on eTrueNorth's technology platform, the individuals can find a nearby location, schedule an appointment, print a voucher and when they arrive onsite, the test results are provided in about ten minutes. The rapid testing is funded by HHS. To schedule an appointment at one of the 22 COVID-19 rapid testing sites in Wisconsin, the individuals should visit www.doineedacovid19test.com for details.

The BioSticker medical device will be worn by study participants for 14 days and will monitor their temperature, respiration rate at rest, heart rate at rest, sleep/rest/active state, body position and/or coughing frequency. The BioSticker data will automatically transmit via the BioHub wireless gateway to the study database for analysis and validation of the BioSignature COVID-19 symptom detection algorithm.